Payment overview · 2025
General Payments
$332.76
19 reported records · 11 companies
Healthcare provider profile · identity verified
Timothy Pauly, MD
Allopathic & Osteopathic Physicians|Family Medicine · HUTCHINSON, KS · NPI 1215909650
Verified facts
What the public records show
CMS Open Payments records show Timothy Pauly, MD received $332.76 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $78.33 | 23.5% | 5 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $53.84 | 16.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.88 | 13.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.48 | 11.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$27.08 | 8.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.36 | 4.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.22 | 4.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.52 | 4.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.39 | 4.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $15.31 | 4.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.35 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $332.76 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $78.33 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.15 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.48 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $27.08 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 582 | 133 |
| Lisinopril | Lisinopril | 454 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 380 | 109 |
| Omeprazole | Omeprazole | 339 | 91 |
| Simvastatin | Simvastatin | 320 | 82 |
| Metformin Hcl | Metformin Hcl | 290 | 84 |
| Sertraline Hcl | Sertraline Hcl | 284 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 276 | 71 |
| Gabapentin | Gabapentin | 272 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 220 | 59 |
| Meloxicam | Meloxicam | 217 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 215 | 66 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 200 | 51 |
| Potassium Chloride | Potassium Chloride | 188 | 52 |
| Losartan Potassium | Losartan Potassium | 180 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 37 |
| Prednisone | Prednisone | 143 | 112 |
| Furosemide | Furosemide | 138 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 131 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 109 | 24 |
| Alprazolam | Alprazolam | 107 | 36 |
| Tramadol Hcl | Tramadol Hcl | 102 | 19 |
| Allopurinol | Allopurinol | 100 | 27 |
| Montelukast Sodium | Montelukast Sodium | 100 | 33 |
| Lovastatin | Lovastatin | 89 | 16 |
| Amoxicillin | Amoxicillin | 87 | 72 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 16 |
| Trazodone Hcl | Trazodone Hcl | 75 | 19 |
| Glipizide | Glipizide | 68 | 18 |
| Ozempic | Semaglutide | 66 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 14 |
| Eliquis | Apixaban | 60 | 13 |
| Celecoxib | Celecoxib | 57 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 17 |
| Synthroid | Levothyroxine Sodium | 56 | 12 |
| Alendronate Sodium | Alendronate Sodium | 54 | 14 |
| Buspirone Hcl | Buspirone Hcl | 54 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 12 |
| Carvedilol | Carvedilol | 51 | 14 |
| Finasteride | Finasteride | 50 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 17 |
| Ondansetron Odt | Ondansetron | 49 | 15 |
| Famotidine | Famotidine | 47 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 46 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 35 |
| Atenolol | Atenolol | 44 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 33 |
| Terazosin Hcl | Terazosin Hcl | 37 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | 19 |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 27 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 12 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Acyclovir | Acyclovir | 21 | suppressed |
| Glyburide | Glyburide | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $332.76 · 19 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, ELIQUIS, GEMTESA, INTELLIS ADAPTIVESTIM, NURTEC ODT, Omnipod, Ozempic, PREVNAR 20, REXULTI, Rybelsus, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error